Jennison Associates
OCUL icon

Jennison Associates’s Ocular Therapeutix OCUL Stock Holding History

Jennison Associates’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$745K Buy
75,829
+3,318
+5% +$30.1K ﹤0.01% 528
2026
Q1 		$614K Buy
+72,511
New +$691K ﹤0.01% 537
2019
Q2 		– Sell
-252,708
Closed -$1M – 667
2019
Q1 		$1M Sell
252,708
-1,379,938
-85% -$5.55M ﹤0.01% 541
2018
Q4 		$6.5M Sell
1,632,646
-703,343
-30% -$3.88M 0.01% 467
2018
Q3 		$16.1M Buy
2,335,989
+16,734
+0.7% +$105K 0.01% 425
2018
Q2 		$15.7M Buy
2,319,255
+26,503
+1% +$182K 0.02% 430
2018
Q1 		$14.9M Buy
2,292,752
+297,984
+15% +$1.68M 0.01% 428
2017
Q4 		$8.88M Buy
1,994,768
+20,132
+1% +$103K 0.01% 471
2017
Q3 		$12.2M Sell
1,974,636
-10,860
-0.5% -$69.9K 0.01% 461
2017
Q2 		$18.4M Sell
1,985,496
-1,231,385
-38% -$11.9M 0.02% 420
2017
Q1 		$29.9M Hold
3,216,881
– – 0.03% 363
2016
Q4 		$26.9M Buy
3,216,881
+212,360
+7% +$1.65M 0.03% 371
2016
Q3 		$20.6M Buy
3,004,521
+31,915
+1% +$195K 0.02% 405
2016
Q2 		$14.7M Buy
2,972,606
+1,643,261
+124% +$16.3M 0.02% 437
2016
Q1 		$12.8M Buy
1,329,345
+648,468
+95% +$4.91M 0.01% 442
2015
Q4 		$6.38M Sell
680,877
-89,355
-12% -$965K 0.01% 506
2015
Q3 		$10.8M Buy
770,232
+3,953
+0.5% +$79.4K 0.01% 504
2015
Q2 		$16.1M Buy
766,279
+627,861
+454% +$15.6M 0.01% 480
2015
Q1 		$5.81M Buy
+138,418
New +$4.55M 0.01% 513

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates's OCUL Position: Q2 2026 in Review

Jennison Associates increased its Ocular Therapeutix (OCUL) stake by 4.6% in Q2 2026, buying an estimated $30.1K and bringing the position to 75,829 shares worth $745K. The position accounts for ﹤0.01% of the portfolio, ranked #528.

Jennison Associates first reported a position in OCUL in Q1 2015 and has held it in 19 quarters since. The position peaked at $29.9M in Q1 2017. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Jennison Associates held 75,829 shares of Ocular Therapeutix worth $745K as of Q2 2026.
  • Jennison Associates bought 3,318 Ocular Therapeutix shares in Q2 2026, an estimated $30.1K.
  • Ocular Therapeutix made up ﹤0.01% of Jennison Associates's portfolio in Q2 2026, its #528 holding.
  • Jennison Associates first reported a position in Ocular Therapeutix in Q1 2015 and has held it in 19 quarters since.
  • Jennison Associates's Ocular Therapeutix position peaked at $29.9M in Q1 2017.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.